Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers

Abstract

Through estimating the fraction of the PD-1^hiCD8⁺ T cell, our signature could predict response to ICI therapy across multiple cancers and could serve as a complementary biomarker to TMB.